KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

D3/Penta 21 clinical trial design: A randomised non-inferiority trial with nested drug licensing substudy to assess dolutegravir and lamivudine fixed dose formulations for the maintenance of virological suppression in children with HIV-1 infection, aged 2 to 15 years.

Anna Turkova, Man K Chan, Cissy Kityo, Adeodata R Kekitiinwa, Philippa Musoke, Avy Violari, Ebrahim Variava, Moherndran Archary, Tim R Cressey, Suwalai Chalermpantmetagul, Kanokkorn Sawasdichai, Pradthana Ounchanum, Suparat Kanjanavanit, Sakulrat Srirojana, Ussanee Srirompotong, Steven Welch, Alasdair Bamford, Cristina Epalza, Clàudia Fortuny, Angela Colbers, Eleni Nastouli, Simon Walker, Dan Carr, Magda Conway, Moira J Spyer, Nazia Parkar, Iona White, Alessandra Nardone, Margaret J Thomason, Rashida A Ferrand, Carlo Giaquinto, Deborah Ford, D3 trial team

Contemp Clin Trials 142 107540

PMID38636725
PMCIDPMC7618164
DOI10.1016/j.cct.2024.107540
发表日期2024-04-18
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: There is increasing interest in utilising two-drug regimens for HIV treatment with the goal of reducing toxicity and improve acceptability. The D3 trial evaluates the efficacy and safety of DTG/3TC in children and adolescents and includes a nested pharmacokinetics(PK) substudy for paediatric drug licensing. METHODS: D3 is an ongoing open-label, phase III, 96-week non-inferiority randomised controlled trial(RCT) conducted in South Africa, Spain, Thailand, Uganda and the United Kingdom. D3 has enrolled 386 children aged 2- < 15 years, virologically suppressed for ≥6 months, with no prior treatment failure. Participants were randomised 1:1 to receive DTG/3TC or DTG plus two nucleoside reverse transcriptase inhibitors(NRTIs), stratified by region, age (2- < 6, 6- < 12, 12- < 15 years) and DTG use at enrolment (participants permitted to start DTG at enrolment). The primary outcome is confirmed HIV-1 RNA viral rebound ≥50 copies/mL by 96-weeks. The trial employs the Smooth Away From Expected(SAFE) non-inferiority frontier, which specifies the non-inferiority margin and significance level based on the observed event risk in the control arm. The nested PK substudy evaluates WHO weight-band-aligned dosing in the DTG/3TC arm. DISCUSSION: D3 is the first comparative trial evaluating DTG/3TC in children and adolescents. Implications of integrating a PK substudy and supplying data for prompt regulatory submission, were carefully considered to ensure the integrity of the ongoing trial. The trial uses an innovative non-inferiority frontier for the primary analysis to allow for a lower-than-expected confirmed viral rebound risk in the control arm, while ensuring interpretability of results and maintaining the planned sample size in an already funded trial. TRIAL REGISTRATION: International Standard Randomised Clinical Trial Number Register: ISRCTN17157458. European Clinical Trials Database: 2020-001426-57. CLINICALTRIALS: gov: NCT04337450.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。